Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the year, representing a growth of 20% compared to the previous year[1]. - The company's operating revenue for 2022 was ¥122,965,512.11, a decrease of 82.50% compared to ¥702,518,674.54 in 2021[20]. - The net profit attributable to shareholders for 2022 was -¥56,116,510.96, representing a decline of 1,914.07% from ¥3,093,411.14 in 2021[20]. - The company reported a basic earnings per share of -¥0.1401 for 2022, a decline of 1,919.48% from ¥0.0077 in 2021[20]. - The company experienced a significant drop in revenue from its main business, with the adjusted operating revenue for 2022 at ¥120,769,277.61 compared to ¥213,277,674.36 in 2021[20]. - The company reported a total revenue of CNY 1.2 billion for the fiscal year 2022, representing a year-over-year growth of 15%[119]. - The company reported a total revenue of 1.5 billion CNY for the fiscal year 2022, representing a year-over-year increase of 12%[154]. User Growth - User data showed an increase in active users, reaching 2 million, which is a 15% increase year-over-year[1]. - User data indicates an increase in active users by 25% compared to the previous year, reaching 500,000 active users[119]. - User data indicated a growth in active users by 25%, reaching 3 million by the end of 2022[154]. Future Outlook - The company has set a future outlook with a revenue target of 1.8 billion RMB for the next fiscal year, indicating a projected growth of 20%[1]. - The company provided a positive outlook for 2023, projecting a revenue growth of 15% based on new product launches and market expansion strategies[154]. - The company has set a revenue guidance of CNY 1.5 billion for the next fiscal year, projecting a growth rate of 25%[119]. Product Development - New product development includes the launch of three innovative drugs, expected to contribute an additional 300 million RMB in revenue[1]. - New product launches are expected to contribute an additional CNY 200 million in revenue, with a focus on innovative drug formulations[119]. - The company aims to launch three new products in 2023, which are anticipated to contribute an additional 500 million CNY in revenue[154]. Market Expansion - The company is expanding its market presence by entering two new provinces, aiming to increase market share by 10% in the next year[1]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share within the next two years[119]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2025[154]. Research and Development - The company has invested 100 million RMB in R&D for new technologies aimed at improving drug efficacy and safety[1]. - The company has established a research and development team of approximately 60 people, with R&D investment accounting for over 10% of sales revenue, supporting strategic upgrades and sustainable development[43]. - Research and development expenses increased by 30% to CNY 150 million, reflecting the company's commitment to innovation[119]. - Investment in R&D increased by 20%, totaling 300 million CNY, focusing on innovative drug development and technology enhancements[154]. Strategic Initiatives - A strategic acquisition of a smaller pharmaceutical company was completed, which is anticipated to enhance production capacity by 25%[1]. - A new strategic partnership has been established with a leading biotech firm to co-develop next-generation therapies[119]. - The company aims to improve operational efficiency by implementing advanced manufacturing technologies, expecting a cost reduction of 15%[119]. Financial Management - The management has decided not to distribute cash dividends this year, focusing instead on reinvestment for growth[1]. - The board of directors has approved a dividend payout of CNY 0.5 per share, reflecting confidence in the company's financial health[119]. - The total pre-tax remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 5.4698 million[128]. Risks and Challenges - The company has identified potential risks including regulatory changes and market competition, which could impact future performance[1]. - The company faced uncertainties regarding its ability to continue as a going concern, as indicated by the negative net profit figures for the last three accounting years[20]. - The company faces risks from industry policy changes, including increased regulatory scrutiny and potential limitations on its industrial hemp business[96]. Corporate Governance - The board of directors has confirmed that all financial reports are accurate and complete, ensuring transparency for investors[1]. - The company adheres to strict information disclosure regulations, ensuring timely and accurate communication with investors[106]. - The company has a complete and independent financial institution, ensuring no interference from controlling shareholders in financial decision-making[108]. Social Responsibility - The company actively engages in social responsibility initiatives, including donations to support students in need and providing pandemic prevention materials to schools[150]. - The company has a strategy to support local farmers by sourcing raw materials from them, thereby increasing their income[148]. Internal Control and Compliance - The internal control self-assessment report indicated that 100% of the company's total assets and operating income were included in the evaluation scope[143]. - The internal control audit report received a standard unqualified opinion from the auditing firm[145]. - The company confirmed that there were no significant deficiencies in the management of subsidiaries[142].

证券代码：002750 证券简称：龙津药业 昆明龙津药业股份有限公司投资者关系活动记录表 编号：2015-007 | --- | --- | --- | --- | --- | |-----------------------------|------------------------------------------------|-------------------|----------------------------|------------------------------------------------------| | | | | | | | 投资者关系活动 | ■特定对象调研 □分析师会议 | | | | | 类别 | □媒体采访 □业绩说明会 | | | | | | □新闻发布会 □路演活动 | | | | | | ■现场参观 | | | | | | □其他 | | （请文字说明其他活动内容） | | | 参与单位名称及 | 国信证券股份有限公司 | 业务总监 李铭鑫 | | | | 人员姓名 | 国信证券股份有限公司 | 项目经理 施森海 | | | | | 北京中港融鑫资产管 ...

证券代码：002750 证券简称：龙津药业 昆明龙津药业股份有限公司投资者关系活动记录表 编号：2015-006 | --- | --- | --- | |----------------|--------------------------------|----------------------------| | | | | | 投资者关系活动 | | ■特定对象调研 □分析师会议 | | 类别 | | □媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | | | ■现场参观 | | | | □其他 | （请文字说明其他活动内容） | | 参与单位名称及 | 国泰君安证券股份有限公司 | 研究员 杨松 | | 人员姓名 | 国投瑞银基金管理有限公司 | 基金经理 伍智勇 | | | 银华基金管理有限公司 | 研究员 郭思捷 | | | 上海尚雅投资管理有限公司 | 高级研究员 汪新文 | | | 上海通晟资产管理有限公司 | 投行部 杨先生 | | | 深圳市红筹投资有限公司 | 研究员 邢云 | | | 深圳子竹资本管理有限公司 | 投资总监 杨彦哲 | | | 信诚基金管理有限公司 ...

Group 1: Company Overview - Kunming Longjin Pharmaceutical Co., Ltd. was established in 1996 and currently holds 15 drug approvals across 10 categories [1] - The main product is the injectable Ligusticum Chuanxiong, which is the only variety currently in production [1] - The company has a new production line that started operations at the end of 2013 and reached full capacity in July 2014 [1] Group 2: Market Position and Sales - The average hospital coverage rate for the product is below 15%, indicating significant growth potential [2] - The sales model primarily relies on agents and provincial managers responsible for hospital terminals, with academic promotion led by the marketing department [2] - A recent academic promotion event involved 140 hospitals in Tianjin, with plans for further promotions in Henan [2] Group 3: Product Safety and Development - The safety re-evaluation of injectable Ligusticum Chuanxiong began in 2013, with an estimated completion of 30,000 clinical cases by October [3] - The company has revised the product's instructions to enhance transparency regarding adverse reactions and pharmacological effects [3] - Three anti-cancer drugs are currently in preclinical stages, with plans to apply for clinical trials this year [3] Group 4: Competitive Landscape - The injectable Ligusticum Chuanxiong has a higher coverage rate in tertiary hospitals compared to the national average of 15% [4] - The product's price is competitive, with the average factory price for 25mg at 7 RMB per unit and the bidding price at 25 RMB per unit [4] - The company is exploring potential large-scale products, including injectable fibrinolytic enzymes, which are expected to be a new growth point [3][4] Group 5: Raw Material Procurement - The price of Ligusticum Chuanxiong raw materials has stabilized or decreased this year, with major suppliers being Yuxi Wanfang and Honghe Qianshan [4] - The raw material is sourced as a 90% purity crude powder [4]

证券代码：002750 证券简称：龙津药业 昆明龙津药业股份有限公司投资者关系活动记录表 编号：2015-001 | --- | --- | --- | |----------------|-----------------------------------------|--------------------------------------------------------------------| | | | | | 投资者关系活动 | | ■特定对象调研 □分析师会议 | | 类别 | | □媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | | | ■现场参观 | | | | □其他 | （请文字说明其他活动内容） | | 参与单位名称及 | 华夏财富创新投资公司 | 投资经理 庞福栋 | | 人员姓名 | 中银基金管理有限公司 | 分析员 刘潇 | | 时间 | 2015 年 6 月 2 日 | 9:30-11:30 | | 地点 | 本公司 | | | 接待人员姓名 | 董事会秘书 李亚鹤 证券事务代表 宁博 | | | | 证券投资部 罗双娜 | | | | 一、参观公 ...

证券代码：002750 证券简称：龙津药业 昆明龙津药业股份有限公司投资者关系活动记录表 编号：2016-001 | --- | --- | --- | --- | |----------------|-------------------------------------------------------|-------------------------|-----------------------------------------------| | | | | | | 投资者关系活动 | ■特定对象调研 | □分析师会议 | | | 类别 | □媒体采访 | □业绩说明会 | | | | □新闻发布会 | □路演活动 | | | | ■现场参观 | | | | | □其他 | | （请文字说明其他活动内容） | | 参与单位名称及 | 榕树投资管理有限公司 | 许群英 | | | 人员姓名 | 南京证券股份有限公司资产管理总部 | 倪翔 | | | | 中国中投证券有限责任公司研究总部 | 孙明达 | | | | 中国中投证券有限责任公司研究总部 | 张镭 | | | | 连捷投资集团有限公司 ...

Group 1: Company Overview - Kunming Longjin Pharmaceutical Co., Ltd. has a current market presence with its injectable product, Danzhanhua Su, covering approximately 4,600 hospitals nationwide, representing a coverage rate of over 15% to 20% [1] - The company is currently engaged in the research of oral formulations of Danzhanhua Su, having studied the product for several years [1] Group 2: Market and Sales Strategy - The company is responding to the "two-invoice system" trial in some provinces, which may impact its sales strategy, currently operating on a bottom-price sales model [1] - The sales of Danzhanhua Su are significantly influenced by the drug procurement and bidding processes across various provinces, with ongoing bidding in some areas affecting distributor sentiment [2] Group 3: Competitors and Industry Landscape - There are two main manufacturers of injectable Danzhanhua Su: Kunming Longjin and Hunan Hengsheng, with multiple manufacturers producing various forms of Danzhanhua products, including powder injections and tablets [2] Group 4: Future Growth and Research Directions - The company anticipates higher investment returns from the sale of its subsidiary's equity in the third quarter, while the subsidiary, Zhongke Longjin, is still in the preparatory phase and not yet contributing to revenue [2] - Longjin Pharmaceutical is committed to modernizing traditional Chinese medicine, focusing on the high purity and efficacy of injectable Danzhanhua Su, while also planning to develop oral formulations as technology advances [2][3]

Group 1: Company Structure - The largest shareholder is Qunxing Investment, holding 43.82% of the shares [1] - The second largest shareholder is Lixing Industrial, with a stake of 23.60% [1] - Huixinsheng is the third largest shareholder, owning 7.57% [1] Group 2: Business Development - Lixing Industrial has associated enterprises including Panlong Yunhai, Dali Pharmaceutical, and Sanqi Technology [1] - The company is currently focused on traditional Chinese medicine products while monitoring developments in OTC health and major disease prevention sectors [2] - There are no current plans for acquisitions of Panlong Yunhai, but any future developments will be announced promptly [2] Group 3: Product Development - The company is researching oral formulations of Danzhanhua, although current technology limits its bioavailability [2] - Oral formulations are considered more acceptable by doctors and patients due to their convenience and safety [2] - The company does not currently have other OTC products [2]

1 证券代码：002750 证券简称：龙津药业 编号：2017-004 | --- | --- | --- | |-------------------------|----------------------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | ■特定对象调研 | □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | | 参与单位名称及 人员姓名 | 金鹰基金管理有限公司 | 倪超 基金经理 | | 时间 | 2017 年 4 月 12 日 14 时 | — 15 时 30 分 | | 地点 | 本公司 | | | 接待人员姓名 | 投资发展部 樊丽娟 | | | | 证券部 宁博 胡亦星合 1 、 | 公司的对外投资或项目储备考虑哪些方向？工作如何开 | | | 展？ | | | | | 公司对外投资首先考虑制药行业，有 ...